Anjum Zaki

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase I clinical trial of NEO-201, an anti-tumor-associated CEACAM-5/6 monoclonal antibody in solid tumors.”.

Phase I clinical trial of NEO-201, an anti-tumor-associated CEACAM-5/6 monoclonal antibody in solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2531

N/A

0DataRank · unranked

2 citations

Maria Pia Morelli, Massimo Fantini, Marı́a M. Fergusson, Sharon Mavroukakis, Anjum Zaki +4 more

Phase II study combining an anti-core 1 O-glycans targeting humanized monoclonal antibody NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e14515

N/A

0DataRank · unranked

0 citations

Christopher B. Cole, Ann McCoy, Massimo Fantini, Sharon Mavroukakis, Anjum Zaki +4 more

Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2530

N/A

0DataRank · unranked

2 citations

Massimo Fantini, Kwong Y. Tsang, Kevin C. Conlon, Charalampos S. Floudas, Azam Ghafoor +8 more